{"paper_id":"082b0d5e-3bb6-403e-b070-963a77f91d7e","body_text":"The impact of histological subtype on postoperative recurrence pattern and timing in locally advanced esophagogastric junction cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The impact of histological subtype on postoperative recurrence pattern and timing in locally advanced esophagogastric junction cancer Shinsuke Maeda, Masaho Ota, Shunichi Ito, Kei Hosoda This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4063105/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose The differences of tumoral behavior between histological subtypes of esophagogastric junction (EGJ) cancer have yet to be well investigated. The purpose of this study is to gain insights that can contribute to the tailored treatments and follow-up strategies by analyzing correlation between histological subtypes and oncological outcomes. Methods Retrospective analysis was used to determine the characteristics of the histological subtype of EGJ cancer by comparing the appearance of postoperative recurrences. A total of 102 consecutive cases of pathological Stage IIA to IVA EGJ cancer, who underwent R0 surgery in our department from 2004 to 2020, were enrolled. The recurrence pattern, timing, survival, and potential prognostic factors were compared. Results After a median follow-up time of 70.1 months, the AC group demonstrated a comparable lymph node metastasis-free survival (P = 0.291) and a significantly worse non-lymphogenous failure-free survival (P = 0.035) than the SCC group. A significantly longer period from surgery to recurrence in the AC group was also observed (P = 0.029). Multivariate analysis indicated that histological subtype (P = 0.015, 95% CI = 1.24–7.28) was significantly correlated with the incidence of non-lymphogenous recurrence. Conclusions The pattern and timing of postoperative recurrence for EGJ cancer were found to be significantly different between the histological subtypes. EGJ AC may have a stronger tendency of non-lymphogenous progression and a propensity for longer surgery-to-recurrence periods compared to EGJ SCC. esophagogastric junction histological subtype recurrence pattern recurrence timing Figures Figure 1 Figure 2 Figure 3 Introduction In 2020, carcinoma of the esophagus was recorded as the seventh most frequent type of cancer (604,000 new cases) and the sixth most common cause of cancer-related mortality (544,000 deaths) worldwide [ 1 ]. Although squamous cell carcinoma (SCC) is currently the main subtype of esophageal cancer, the incidence rate of esophageal and esophagogastric junction (EGJ) adenocarcinoma (AC) is currently on the rise in high-income countries, including Japan [ 2 – 4 ]. Furthermore, currently available treatment strategies for this type of tumor are highly controversial. The ESMO (European Society for Medical Oncology) clinical practice guidelines for esophageal cancer recommend both perioperative chemotherapy and preoperative chemoradiotherapy (CRT) for resectable locally advanced AC, with controversy regarding which of the two treatments is the better choice [ 5 ]. For resectable locally advanced SCC, preoperative CRT is the only recommended treatment option as perioperative therapy in Western countries. In Japan, however, the NExT study did not demonstrate the survival superiority of preoperative CRT compared to preoperative doublet chemotherapy [ 6 ]. As a result, preoperative triplet DCF (docetaxel, cisplatin, plus 5-FU) therapy has emerged as the primary recommendation. Esophageal SCC and AC have often been treated as a single entity in clinical studies, and few studies have investigated the differences in oncological behavior between these histological subtypes. Understanding the differences in oncological behavior may contribute to the development of a more personalized therapeutic strategy. Thus, in this study, a retrospective investigation was conducted on the appearance of recurrence after surgery for EGJ cancer in relation to histological subtypes. Material and Methods Patient selection A retrospective analysis was conducted on 150 consecutive patients with EGJ carcinoma who underwent surgical resection at Tokyo Women’s Medical University Hospital (Tokyo, Japan) between January 2004 and October 2020. EGJ carcinoma was defined according to Nishi’s classification [ 7 ]. Tumors with their tumor epicenter located between 2 cm proximal and distal from the anatomical EGJ, irrespective of histology, were classified as EGJ carcinomas. Anatomical EGJ was identified from the resected specimen and was defined as the distal end of palisade vessels or deep esophageal glands and ducts. When the EGJ could not be detected microscopically due to tumor invasion, the level of macroscopic caliber change was used to define EGJ. All patients had pretreatment evaluation that included esophagogastroduodenoscopy (EGD) with biopsies, computed tomography scan (CT) from the chest to the pelvis, and/or positron emission tomography (PET). Staging was classified according to the 8th TNM staging system of the Union for International Cancer Control. The inclusion criteria were as follows: (1) pathologically diagnosed squamous cell carcinoma (including basaloid squamous cell carcinoma) or adenocarcinoma, except for adenosquamous carcinoma; (2) no residual tumor under microscope (R0); (3) without concomitant or prior malignancy within 5 years; (4) no history of preoperative endoscopic resection of the primary lesion; (5) not M1 disease at the time of initial diagnosis; (6) pathologically Stage IIA to IVA (T2-4 or N(+), except for M1); (7) followed up with periodic CT and EGD after surgery. This study was approved by the Ethics Review Board of Tokyo Women’s Medical University (Approval number: 4582). Surgery and perioperative treatment The choice of surgical procedure was determined by the length of esophageal involvement, the general condition of the patients, and the experience of the surgeons. For AC with esophageal involvement over 3 cm, transthoracic approach was commonly selected. For AC with esophageal involvement less than 3 cm, transabdominal lower esophagectomy with proximal or total gastrectomy was prevalently performed. For SCC, transthoracic surgery was performed in principle. As for abdominal lymphadenectomy, paracardial, along the left gastric artery, lesser curvature lymph nodes (LNs) along the branches of the left gastric artery, in the esophageal hiatus, and clinically positive LNs were routinely resected. Mediastinal lymphadenectomy included periesophageal and infracarinal when a transthoracic approach was used; the lower mediastinal nodes up to the level of the proximal margin were included with a transabdominal approach. The extent of further lymphadenectomy (including 106rec) depended on the preoperative findings. Digestive tract reconstruction involved the stomach or jejunum. The Clavien-Dindo (CD) classification system was used to assess postoperative complications [ 8 ]. Patients with grade ≥ 2 complications were classified as having complications. For patients with an estimated high risk of postoperative relapse (i.e., T stage > 3 and/or positive N status) and with tolerable organ functions, platinum- or taxane-based neoadjuvant chemotherapy with or without concurrent 40Gy of radiotherapy, and/or adjuvant chemotherapy were performed (Supplementary Table 1). Postoperative surveillance After surgery, the patients were followed up every three months for the first two years, semiannually for the next three years, and annually thereafter. During follow-up, blood tests and a CT scan from the chest to the pelvis were performed at every scheduled interval. EGD was conducted annually. When cancer recurrence was suspected on CT images or laboratory data, positron emission tomography-computed tomography (PET-CT) was additionally performed. Pattern of recurrence Recurrences were diagnosed with histological, cytological, or definite radiological proof. Only the first episode of recurrence was used for analysis. For cases of concurrent multifocal recurrences, each categorized pattern was counted. The local area was defined to include tumor bed, anastomosis, remnant esophagus, and remnant stomach. The area of group 1 and 2 LNs of the Ae (zone of the EGJ) regional tumor on the 11th edition of Japanese Classification of Esophageal Cancer was defined as the regional area [ 9 ]. Patterns of recurrence were first categorized into local recurrence, regional lymph node metastasis, distant lymph node metastasis, distant organ metastasis, and peritoneal or pleural dissemination. Locoregional recurrences (LRR) and systemic metastases (SM) were then classified. Likewise, recurrence except for LN failure was classified as non-lymphogenous recurrence (NLR). The data was last updated in February 2023. Statistical analysis Continuous variables were compared using the Welch’s t-test. Categorical variables were compared using the Chi-square test. Age, primary tumor length, and number of examined LNs were grouped by the median value as a cut-off. Survival times were defined from the date of surgery. The timing of recurrence was calculated from the day of surgery to the first event. The Kaplan-Meier method was used to analyze survival times, and Log-rank test was used to examine intergroup differences. Univariate Cox proportional hazards regression model was used to analyze prognostic factors, and Fine-Gray proportional hazards regression model was used in the multivariate analysis. Covariates with P < 0.1 in the univariate analysis were entered into the multivariate analysis and the backward stepwise method was used to optimize the model. Statistical analyses were conducted using R software version 4.1.2 (The R Foundation for Statistical Computing, Vienna, Austria). P < 0.05 was considered statistically significant. Results Patient characteristics A total of 102 eligible patients with EGJ cancer were analyzed: 48 with SCC and 54 with AC (Fig. 1). The median age of the whole group was 67 years (range, 42-85 years) and the median longitudinal length of the primary tumor in the resected specimen was 53 mm (range, 10-110 mm). A summary of the comparisons between the histology groups is provided in Table 1. An analysis of the patient characteristics revealed no significant intergroup differences in terms of age, tumor diameter and location, number of metastatic LNs, pathological T, N, and TNM stages, lymphatic and venous microinvasions, differentiation of tumor cells, and postoperative complication. Compared to patients with SCC, patients with AC were more frequently male (88.8% vs 64.6%; P = 0.007) and underwent transabdominal surgery more often (38.9% vs 6.3%; P < 0.001). Accordingly, a larger number of LNs were examined in the SCC group (mean number = 21.7 vs 27.9; P = 0.019). A total of 68 patients (66.7%) were administered perioperative treatment. Adjuvant treatment was more frequently administered for AC (57.4% vs 35.4%; P = 0.043), although the frequency of neoadjuvant treatment showed no significant difference (16.7% vs 31.3%; P = 0.134). The aggregate frequency of perioperative treatment was comparable (68.5% vs 64.6%; P = 0.833). Recurrence pattern After a median follow-up time of 70.1 months (interquartile range [IQR], 67.1-95.0 months) for SCC and 70.9 month (IQR, 43.9-98.7 months) for AC in the patients who remained alive, 21 patients (43.8%) with SCC and 33 patients (61.1%) with AC experienced recurrences. The 5-year overall survival (OS) and relapse-free survival (RFS) ratio for SCC vs. AC were 53.7 vs. 39.6% (P = 0.470; Fig. 2a) and 45.0 vs. 33.8% (P = 0.613; Fig. 2b), respectively. A total of 17 patients (35.4%, 7 above and 11 below the diaphragm) experienced LN failure and 7 (14.6%) showed NLR in patients with SCC. In the AC group, 14 patients (25.9%, 6 above and 8 below the diaphragm) showed LN failure and 20 (37.0%) showed NLR (Table 2). The AC group demonstrated a comparable LN failure-free survival (P = 0.291; Fig. 3a) and a significantly worse NLR-free survival (P = 0.035; Fig. 3b) compared with the SCC group. Regarding the areas of relapse, 9 (18.8 %) LRRs and 17 (35.4%) SMs occurred in the SCC group, and 9 (16.7%) LRRs and 27 (50.0%) SMs were observed in the AC group. Both LRR-free and SM-free survivals were comparable between histological subtypes (P = 0.696 and 0.339, respectively). Specific sites of recurrence are listed in Table 2. Liver was the most common distant metastasis site in both groups. Both pleural and peritoneal carcinomatosis were frequent in the AC group and the rate of dissemination was higher in the AC group, although it did not reach statistical significance (14.8% vs 2.1%; P = 0.063). Recurrence timing For patients who experienced recurrences, the median time to the first recurrence was 13.9 months (IQR, 5.9-20.9 months) after surgery in the AC group and 7.0 months (IQR, 4.5-8.7 months) in the SCC group, respectively. The statistical significance of a longer period from surgery to recurrence was observed in the AC group (P = 0.029). Overall, 76.2% of first recurrences for patients with SCC versus 45.5% for those with AC occurred within one year of follow-up. The surgery-to-NLR periods were significantly longer in the AC group (median, 12.2 vs 4.5 months; IQR, 3.8-18.4 vs 4.2-6.0 months; P = 0.007), whereas the surgery-to-LN failure periods were comparable between the two groups (median, 15.1 vs 7.2 months; IQR, 7.7-20.9 vs 4.7-13.3 months; P = 0.095). The timing and frequency of recurrences are listed in Table 3. Prognostic factors for recurrence Univariate and multivariate analyses of prognostic factors for developing NLR were performed (Table 4). Multivariate analysis identified that histological subtype (P = 0.015, 95% CI = 1.24-7.28), pathological TNM stage (P = 0.002, 95% CI = 1.59-7.17), and differentiation (P = 0.029, 95% CI = 1.09-4.89) were independent predictive factors of NLR. Discussion Esophageal and EGJ AC have shown the highest rates of increase in incidence of any cancer over the past four decades, especially in high-income countries [ 2 ]. In recent years, EGJ AC has also increased in Japan [ 3 , 4 ]. On the other hand, esophageal SCC accounts for up to 90% of cases of esophageal cancer worldwide; however, it is decreasing in Western countries [ 5 , 10 ]. These two distinct tumors tend to be considered to share similar characteristics and their differences have rarely been investigated. However, in addition to the previously observed greater male predominance of esophageal AC than esophageal SCC, other differences may also exist [ 11 ]. Regarding differences in the post-therapeutic outcomes, Siewert et al. reported a worse long-term survival among esophageal SCC patients compared to AC patients in patients undergoing surgery alone at the beginning of the twenty-first century [ 12 ]. Thereafter, the CROSS trial demonstrated similar LRR rates between the two histology groups of esophageal or EGJ cancer, in patients who received neoadjuvant CRT followed by surgery, whereas a higher risk of LRR for SCC was observed in patients who only underwent surgery [ 13 ]. As for systemic failure, conflicting outcomes regarding its likeliness in relation with histology, brought by varied protocols of trimodality therapy, have been reported [ 14 , 15 ]. Concerning treatment modalities other than surgery-based treatment, Xi et al. retrospectively compared esophageal cancer cases by definitive CRT and reported significantly more favorable hematogenous failure-free survival in SCC patients and significantly higher rates of distant failure in AC patients [ 16 ]. However, the locational distributions of the two histological subtypes can vary, and previous studies present a bias in terms of tumor location between the two histological subtypes. This study is the first to compare postoperative recurrence patterns and timing between histological subtypes in an EGJ-limited-cancer cohort and identify differences. As a result, a significantly worse postoperative non-lymphogenous failure-free survival and significantly longer period from surgery to recurrence was observed in the AC group compared to the SCC group. In contrast, a relatively higher recurrence rate at LN was observed in the SCC group, even though the SCC group showed a larger number of harvested LNs and a smaller number of metastatic LNs. Studies involving lager cohorts that focused on individual histological subtypes have shown that the primary cause of postoperative failure in esophageal SCC was often LN metastasis [ 17 ]. Conversely, LN metastasis was a less common factor contributing to postoperative failure in EGJ AC [ 18 ]. The findings of the present study agree with those of previous studies, suggesting that assessing tumor-spreading appearance based on a viewpoint lymphogenous or non-lymphogenous, rather than focusing solely on locoregional or systemic aspects, may provide more informative insights. Concerning recurrence timing, median time-to-recurrence after surgery in esophageal and EGJ AC has been reported within a range of between 11 and 26 months [ 19 – 21 ]. In esophageal SCC, Kurogochi et al. reported that over 70% of postoperative recurrence occurred within one year [ 22 ]. To the best of our knowledge, there have been no direct comparisons of the timing of postoperative recurrence between histological subtypes in esophageal or EGJ cancer. Yun et al. directly compared the timing of recurrence after surgery for non-small cell lung cancer and found varied peaks of recurrence hazard depending on tumor histology; 9 months in SCC and 15 months in AC [ 23 ]. These findings closely resemble our results, suggesting that longer periods until recurrence in AC than in SCC may be a common tumoral characteristic across primary organs, considering findings in the field of lung cancer. Treatment strategies for esophageal and EGJ AC have mainly been developed in Western countries. In the CROSS trial, conducted in a cohort among which 75% of patients had esophageal or EGJ AC, the effect of neoadjuvant chemoradiotherapy tended to be lower for AC than for SCC. Furthermore, the ten-year outcomes did not show significant survival superiority in the AC group [ 24 , 25 ]. A high ratio (28.6%) of hematogenous recurrence after the neoadjuvant chemoradiotherapy was also noted. 13 The FLOT4-AIO trial demonstrated a significantly enhanced outcome with perioperative FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) therapy for EGJ and gastric AC, compared with perioperative ECF/ECX (MAGIC regimen) therapy [ 26 ]. For esophageal or EGJ cancer after neoadjuvant CRT, significantly longer disease-free survival for both AC and SCC were associated with adjuvant nivolumab therapy in the Checkmate 577 trial [ 27 ]. In the Neo-AEGIS trial, trimodality therapy was directly compared with perioperative chemotherapy for AC of the esophagus and EGJ [ 28 ]. This study ended in equipoise, with significantly fewer liver and lung metastases in the perioperative chemotherapy group. The current study indicates that EGJ AC may exhibit a stronger tendency for non-lymphogenous progression compared to EGJ SCC. This may be a favorable factor for treatment emphasizing systemic control since non-lymphogenous progression is more challenging to manage through surgical resection or by radiation therapy than progression through the lymphatic system. Comprehensively, both the findings reported in the literature and the results of the present study suggest that perioperative systemic treatment would be promising for EGJ AC. This study has some limitations, including its retrospective, single-center design. Possibility of selection bias cannot be excluded. Second, variations of treatments could have influenced the results. Surgical approach and the extent of LN dissection, where a consensus has not made, varied between the subgroups while R0 was secured in all cases, and both the incidence of postoperative complication and the distribution of LN metastasis site were comparable. Differences in perioperative treatments also might have affected the result. Third is the small number of the cases. Nevertheless, given the rarity of EGJ SCC, we believe this study is valuable in terms of the study of aspects that have rarely been investigated before. Furthermore, this study is the first to note the different pattern and varied timing of postoperative recurrence in EGJ cancers. Future research with larger and characteristically well-matched cohorts to verify these findings will be desirable and beneficial. Conclusions EGJ AC showed a stronger tendency for non-lymphogenous progression and a propensity for longer surgery-to-recurrence period compared to EGJ SCC. Thus, emphasizing perioperative systemic control would be suitable for resectable locally advanced EGJ AC. In this context, careful attention should be paid to the different patterns and timing of recurrence for the different histological subtypes of EGJ cancer in the postoperative follow-up period. Declarations Acknowledgments We would like to thank Editage (www.editage.jp) for English language editing. Ethics Statements This study was conducted with approval of the Ethics Review Board of Tokyo Women’s Medical University (Approval number: 4582) and conforms to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). Requirement for written informed consent was waived due to the retrospective design. Competing Interests The Authors declare that they have no conflicts of interest in relation to this study. Funding Information No funding was received for conducting this study. Author Contribution S.M. and M.O. substantially contributed to the study design. S.M. and S.I. significantly contributed to data acquisition, analysis, and interpretation. S.M. and K.H. substantially contributed to the manuscript drafting. All authors reviewed the manuscript. References Sung H, Ferlay J, Siegel RL, et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-49.https://doi.org/10.3322/caac.21660 Coleman HG, Xie SH, Lagergren J (2018) The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 154(2):390–405.https://doi.org/10.1053/j.gastro.2017.07.046 Kusano C, Gotoda T, Khor CJ, et al (2008) Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 23(11):1662-5.https://doi.org/10.1111/j.1440-1746.2008.05572.x Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M (2017) Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 20:69–83.https://doi.org/10.1007/s10120-016-0663-8 Obermannová R, Alsina M, Cervantes A, et al (2022) Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 33(10):992–1004.https://doi.org/10.1016/j.annonc.2022.07.003 Kato K, Ito Y, Daiko H, et al (2022) A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 40(4_suppl):238.https://doi.org/10.1200/jco.2022.40.4_suppl.238 Japan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus. 14(1):37-65.https://doi.org/10.1007/s10388-016-0556-2 Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240(2):205-13.https://doi.org/10.1097/01.sla.0000133083.54934.ae Japan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 14(1):1-36.https://doi.org/10.1007/s10388-016-0551-7 Arnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64(3):381–7.https://doi.org/10.1136/gutjnl-2014-308124 Turner KO, Genta RM, Sonnenberg A (2015) Oesophageal signet ring cell carcinoma as complication of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 42(10):1221-31.https://doi.org/10.1111/apt.13395 Siewert JR, Engl F, Stein HJ, et al (2001) Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World. Ann Surg. 234:360–7.https://doi.org/10.1097/00000658-200109000-00010 Oppedijk V, Van Der Gaast A, Van Lanschot JJB, et al (2014) Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 32(5):385–91.https://doi.org/10.1200/JCO.2013.51.2186 Robb WB, Messager M, Dahan L, et al (2016) Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 103(1):117–25.https://doi.org/10.1002/bjs.9959 Koshy M, Greenwald BD, Hausner P, et al (2011) Outcomes after trimodality therapy for esophageal cancer: The impact of histology on failure patterns. Am J Clin Oncol. 34(3):259–64.https://doi.org/10.1097/COC.0b013e3181e841ce Xi M, Xu C, Liao Z, et al (2017) The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 124(2):318–24.https://doi.org/10.1016/j.radonc.2017.06.019 Sugimura K, Miyata H, Kanemura T, et al (2023) Patterns of Recurrence and Long-Term Survival of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Locally Advanced Esophageal Cancer Treated with Neoadjuvant Chemotherapy: a Propensity Score–Matched Analysis. J Gastrointest Surg. 27(6):1055-65.https://doi.org/10.1007/s11605-023-05615-x Nakauchi M, Vos EL, Carr RA, et al (2023) Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021. Ann Surg. 277(4):629–36.https://doi.org/10.1097/SLA.0000000000005320 de Manzoni G, Pedrazzani C, Pasini F, et al (2003) Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol. 29(6):506–10.https://doi.org/10.1016/S0748-7983(03)00098-2 Hosokawa Y, Kinoshita T, Konishi M, et al (2014) Recurrence patterns of esophagogastric junction adenocarcinoma according to Siewert’s classification after radical resection. Anticancer Res. 34(8):4391-7. Abate E, DeMeester SR, Zehetner J, et al (2010) Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and Testing. J Am Coll Surg. 210(4):428-35.https://doi.org/10.1016/j.jamcollsurg.2010.01.006 Kurogochi T, Honda M, Takahashi K, et al (2022) Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer. Surg Today. 52(4):660–7.https://doi.org/10.1007/s00595-021-02397-0 Yun JK, Lee GD, Choi S, et al (2022) Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection. Transl Lung Cancer Res. 11(7):1327–36.https://doi.org/10.21037/tlcr-21-1028 Van Hagen P, Hulshof MCCM, Van Lanschot JJB, et al (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med. 366:2074–84.https://doi.org/10.1056/NEJMoa1112088 Eyck BM, Van Lanschot JJB, Hulshof MCCM, et al (2021) Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 39:1995–2004.https://doi.org/ 10.1200/JCO.20.03614 Al-Batran SE, Homann N, Pauligk C, et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 393(10184):1948–57.https://doi.org/10.1016/S0140-6736(18)32557-1 Kelly RJ, Ajani JA, Kuzdzal J, et al (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 384(13):1191-203.https://doi.org/10.1056/nejmoa2032125 Reynolds JV, Preston SR, O’Neill B, et al (2023) Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 8(11):1015–27. https://doi.org/10.1016/S2468-1253(23)00243-1 Tables Table 1 Background characteristics and pathological findings of the patients Characteristic All patients (n = 102) SCC (n = 48) AC (n = 54) p Value n (%) n (%) n (%) Age, years 0.094 Median 67 69.5 67 Range 42-85 48-85 42-84 Gender 0.007 Male 79 (77.5) 31 (63.5) 48 (88.9) Female 23 (22.5) 17 (35.4) 6 (11.1) Tumor diameter, mm 0.549 Median 53 52.5 53 Range 10-110 10-105 16-110 Tumor location 0.269 Across the EGJ 94 (92.2) 43 (89.6) 51 (94.4) Esophagus only 7 (6.9) 5 (10.4) 2 (3.7) Stomach only 1 (1.0) 0 (0.0) 1 (1.9) Surgical procedure <0.001 Transthoracic 78 (76.5) 45 (93.8) 33 (61.1) Transabdominal 24 (23.5) 3 (6.2) 21 (38.9) Number of examined LNs (mean ± SD) 24.6 ± 13.1 27.9 ± 14.1 21.7 ± 11.5 0.019 Number of metastatic LNs (mean ± SD) 3.10 ± 3.59 2.60 ± 2.83 3.54 ± 4.12 0.182 Postoperative complication a 1.00 Yes 21 (20.6) 10 (20.8) 11 (20.4) No 81 (79.4) 38 (79.2) 43 (79.6) Perioperative treatment (+/-) 0.833 Yes 68 (66.7) 31 (64.6) 37 (68.5) No 34 (33.3) 17 (35.4) 17 (31.5) Neoadjuvant treatment (+/-) 0.134 Yes 24 (23.5) 15 (31.3) 9 (16.7) No 78 (76.5) 33 (68.8) 45 (83.3) Adjuvant treatment (+/-) 0.043 Yes 48 (47.1) 17 (35.4) 31 (57.4) No 54 (52.9) 31 (64.6) 23 (42.6) Pathological T stage b 0.378 1 8 (78.4) 3 (6.3) 5 (9.3) 2 11 (10.8) 4 (3.9) 7 (13.0) 3 81 (79.4) 39 (81.3) 42 (77.8) 4 2 (2.0) 2 (4.2) 0 (0.0) Pathological N stage b 0.164 0 30 (29.4) 14 (29.2) 16 (29.6) 1 32 (31.4) 15 (14.7) 17 (35.4) 2 22 (21.6) 14 (29.2) 8 (14.8) 3 18 (17.6) 5 (4.9) 13 (24.1) Pathological TNM stage b 0.150 IIA 7 (6.9) 4 (8.3) 3 (5.6) IIB 29 (28.4) 12 (25.0) 17 (31.5) IIIA 6 (5.9) 1 (2.1) 5 (9.3) IIIB 40 (39.2) 24 (50.0) 16 (29.6) IVA 20 (19.6) 7 (14.6) 13 (24.1) Lymphatic microinvasion 1.00 None or slight 47 (46.1) 22 (45.8) 25 (46.3) Moderate or severe 55 (53.9) 26 (54.2) 29 (53.7) Venous microinvasion 0.948 None or slight 73 (71.6) 35 (72.9) 38 (70.4) Moderate or severe 29 (28.4) 13 (27.1) 16 (29.6) Differentiation of tumor cells 0.530 Well or moderate 68 (66.7) 34 (70.8) 34 (63.0) Poor 34 (33.3) 14 (29.2) 20 (37.0) a Grade ³ 2 according to the Clavien-Dindo (CD) classification system b The 8th TNM staging system of the Union for International Cancer Control (UICC) SCC squamous cell carcinoma, AC adenocarcinoma, EGJ esophagogastric junction, LN lymph node, CD Clavien-Dindo Table 2 Recurrence patterns SCC (n = 48) AC (n = 54) No. of patients with any relapse: n (%) 21 (43.8) 33 (61.1) Lymphogenous: n (%) 17 (35.4) 14 (25.9) Regional LN 7 3 (above / below the diaphragm) (2/5) (1/2) Distant LN 14 12 (above / below the diaphragm) (7/7) (6/6) Non-lymphogenous: n (%) 7 (14.6) a 20 (37.0) a Local 2 6 Anastomosis 2 0 Tumor bed 0 4 Remnant esophagus 0 2 Systemic 5 15 Liver 2 4 Lung 1 2 Bone 0 1 Adrenal 1 0 Heart 0 1 Pleura 1 4 Peritoneum 0 4 a p < 0.05 SCC squamous cell carcinoma, AC adenocarcinoma, LN lymph node Table 3 Timing and frequency of recurrences a p < 0.05 SCC squamous cell carcinoma, AC adenocarcinoma Table 4 Univariate and multivariate analyses for non-lymphogenous recurrence Variable n Incidence n (%) Univariate Multivariate Hazard ratio (95% CI) p Value Hazard ratio (95% CI) p Value Age <68 / ³68 52 / 50 19 (36.5) / 12 (24.0) 0.63 (0.29-1.37) 0.244 Gender male / female 79 / 23 23 (29.1) / 4 (17.4) 0.62 (0.22-1.81) 0.385 Histological subtype SCC / AC 48 / 54 7 (14.6) / 20 (37.0) 2.45 (1.04-5.81) 0.041 3.00 (1.24-7.28) 0.015 Tumor length £5.0 / >5.0 cm 47 / 55 11 (23.4) / 16 (29.1) 1.43 (0.67-3.09) 0.358 Surgical approach transhiatal / transthoracic 24 / 78 9 (37.5) / 18 (23.1) 0.63 (0.28-1.40) 0.257 Number of examined LNs <24 / ³24 52 / 50 14 (26.9) / 13 (26.0) 0.94 (0.44-2.01) 0.883 Postoperative complication a - / + 81 / 21 21 (25.9) / 6 (28.5) 1.15 (0.46-2.85) 0.765 Pathological T stage b T1-2 / T3-4 19 / 83 3 (15.8) / 24 (28.9) 2.41 (0.72-8.01) 0.152 Pathological N stage b N0-1 / N2-3 62 / 40 13 (21.0) / 14 (35.0) 2.73 (1.26-5.89) 0.011 Pathological TNM stage b IIA-IIIA / IIIB-IVA 42 / 60 7 (16.7) / 20 (33.3) 3.12 (1.31-7.44) 0.010 3.37 (1.59-7.17) 0.002 Lympatic microinvasion none or slight / mod or more 47 / 55 7 (14.9) / 20 (36.4) 3.48 (1.46-8.26) 0.005 Venous microinvasion none or slight / mod or more 73 / 29 17 (23.3) / 10 (34.5) 1.85 (0.84-4.07) 0.125 Differentiation well or moderate / other 68 / 34 13 (19.1) / 14 (41.2) 2.52 (1.19-5.38) 0.016 2.31 (1.09-4.89) 0.029 a Grade ³ 2 according to the Clavien-Dindo (CD) classification system b The 8th TNM staging system of the Union for International Cancer Control (UICC) SCC squamous cell carcinoma, AC adenocarcinoma, CD Clavien-Dindo Additional Declarations No competing interests reported. Supplementary Files Suppltable1.xlsx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-4063105\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":true,\"archivedVersions\":[],\"articleType\":\"Research Article\",\"associatedPublications\":[],\"authors\":[{\"id\":278801363,\"identity\":\"5a84ac2f-fa63-4442-bb27-2afa21ac6561\",\"order_by\":0,\"name\":\"Shinsuke Maeda\",\"email\":\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABBklEQVRIiWNgGAWjYJACCSBOYAMSjA0MNnBRZmK1pEkQr4UBouWwBD6VYKDbfvjgjR8MdXl80u3PJGdUnK8zuHbGgOFHDQO7OQ4tZmfSki17GA4Xs8mcMZPccOa2hMHtHAPGnmMMzJYNOLQcyDGT4GE4kNgmkcMm+bDttoQZUAsDbwMDs8EBHFrOv/8m+YehDqgl/Znkw3/nwFoY/+LTciOHTZqHgRmoJcFMcmPDAbAWZry23HhmbC1jcBjkMGPLGceSJfffTis4LHNMArdfzic/vPmmoi5x/oz0hzd7auz4JWcnb3z4psYmGVeIQYABGh/oJIlkdEHCwI50LaNgFIyCUTBMAQDyqllfAZ5NAwAAAABJRU5ErkJggg==\",\"orcid\":\"\",\"institution\":\"Tokyo Women’s Medical University\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Shinsuke\",\"middleName\":\"\",\"lastName\":\"Maeda\",\"suffix\":\"\"},{\"id\":278801364,\"identity\":\"14d1b740-cad0-4925-ba3e-ecf2605f95c0\",\"order_by\":1,\"name\":\"Masaho Ota\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Tokyo Women’s Medical University Yachiyo Medical Center\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Masaho\",\"middleName\":\"\",\"lastName\":\"Ota\",\"suffix\":\"\"},{\"id\":278801365,\"identity\":\"29c19c29-054e-4521-b815-4457d8320500\",\"order_by\":2,\"name\":\"Shunichi Ito\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Tokyo Women’s Medical University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Shunichi\",\"middleName\":\"\",\"lastName\":\"Ito\",\"suffix\":\"\"},{\"id\":278801366,\"identity\":\"f5c07825-e6e4-4b3a-909e-7da87badc2bd\",\"order_by\":3,\"name\":\"Kei Hosoda\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Tokyo Women’s Medical University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Kei\",\"middleName\":\"\",\"lastName\":\"Hosoda\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2024-03-10 08:16:36\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-4063105/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-4063105/v1\",\"draftVersion\":[],\"editorialEvents\":[],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":52623664,\"identity\":\"eda699b5-6565-4911-8618-664e0cac2ce3\",\"added_by\":\"auto\",\"created_at\":\"2024-03-13 17:21:04\",\"extension\":\"png\",\"order_by\":1,\"title\":\"Figure 1\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":92057,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003eFlow diagram of patients. \\u003cem\\u003eEGJ\\u003c/em\\u003e esophagogastric junction, \\u003cem\\u003eNEC\\u003c/em\\u003eneuroendocrine carcinoma, \\u003cem\\u003eER\\u003c/em\\u003e endoscopic resection\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"floatimage1.png\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4063105/v1/4d5ba7be759f6bdfa4619b5a.png\"},{\"id\":52623640,\"identity\":\"9db9796c-e05f-4915-ae29-3170e68d58a9\",\"added_by\":\"auto\",\"created_at\":\"2024-03-13 17:20:57\",\"extension\":\"png\",\"order_by\":2,\"title\":\"Figure 2\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":430861,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003eKaplan-Meier curves for overall survival (a) and relapse-free survival (b) for patients with esophagogastric junction adenocarcinoma (AC) or squamous cell carcinoma (SCC).\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"floatimage2.png\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4063105/v1/c33ddef41d5c78abc3b1da14.png\"},{\"id\":52623660,\"identity\":\"a24fa7ea-ad08-4fef-b591-804b7475c789\",\"added_by\":\"auto\",\"created_at\":\"2024-03-13 17:20:59\",\"extension\":\"png\",\"order_by\":3,\"title\":\"Figure 3\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":423269,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003eKaplan-Meier curves for lymph node failure-free survival (a) and non-lymphogenous recurrence-free survival (b) for patients with esophagogastric junction adenocarcinoma (AC) or squamous cell carcinoma (SCC).\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"floatimage3.png\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4063105/v1/0b609df859bf7ed0f9a3cd8d.png\"},{\"id\":52764661,\"identity\":\"fb55a5c6-0636-42ce-bbb9-efd38779f979\",\"added_by\":\"auto\",\"created_at\":\"2024-03-15 13:11:07\",\"extension\":\"pdf\",\"order_by\":0,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":684657,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"manuscript.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4063105/v1/c64686fa-7fef-4c11-93f4-d321c990cd08.pdf\"},{\"id\":52623661,\"identity\":\"cbc65e3e-152b-4055-b727-093942e3f4c1\",\"added_by\":\"auto\",\"created_at\":\"2024-03-13 17:20:59\",\"extension\":\"xlsx\",\"order_by\":1,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"supplement\",\"size\":10403,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"Suppltable1.xlsx\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4063105/v1/bb88e51baac03787887ad2b0.xlsx\"}],\"financialInterests\":\"No competing interests reported.\",\"formattedTitle\":\"The impact of histological subtype on postoperative recurrence pattern and timing in locally advanced esophagogastric junction cancer\",\"fulltext\":[{\"header\":\"Introduction\",\"content\":\"\\u003cp\\u003eIn 2020, carcinoma of the esophagus was recorded as the seventh most frequent type of cancer (604,000 new cases) and the sixth most common cause of cancer-related mortality (544,000 deaths) worldwide [\\u003cspan citationid=\\\"CR1\\\" class=\\\"CitationRef\\\"\\u003e1\\u003c/span\\u003e]. Although squamous cell carcinoma (SCC) is currently the main subtype of esophageal cancer, the incidence rate of esophageal and esophagogastric junction (EGJ) adenocarcinoma (AC) is currently on the rise in high-income countries, including Japan [\\u003cspan additionalcitationids=\\\"CR3\\\" citationid=\\\"CR2\\\" class=\\\"CitationRef\\\"\\u003e2\\u003c/span\\u003e\\u0026ndash;\\u003cspan citationid=\\\"CR4\\\" class=\\\"CitationRef\\\"\\u003e4\\u003c/span\\u003e]. Furthermore, currently available treatment strategies for this type of tumor are highly controversial. The ESMO (European Society for Medical Oncology) clinical practice guidelines for esophageal cancer recommend both perioperative chemotherapy and preoperative chemoradiotherapy (CRT) for resectable locally advanced AC, with controversy regarding which of the two treatments is the better choice [\\u003cspan citationid=\\\"CR5\\\" class=\\\"CitationRef\\\"\\u003e5\\u003c/span\\u003e]. For resectable locally advanced SCC, preoperative CRT is the only recommended treatment option as perioperative therapy in Western countries. In Japan, however, the NExT study did not demonstrate the survival superiority of preoperative CRT compared to preoperative doublet chemotherapy [\\u003cspan citationid=\\\"CR6\\\" class=\\\"CitationRef\\\"\\u003e6\\u003c/span\\u003e]. As a result, preoperative triplet DCF (docetaxel, cisplatin, plus 5-FU) therapy has emerged as the primary recommendation.\\u003c/p\\u003e \\u003cp\\u003eEsophageal SCC and AC have often been treated as a single entity in clinical studies, and few studies have investigated the differences in oncological behavior between these histological subtypes. Understanding the differences in oncological behavior may contribute to the development of a more personalized therapeutic strategy. Thus, in this study, a retrospective investigation was conducted on the appearance of recurrence after surgery for EGJ cancer in relation to histological subtypes.\\u003c/p\\u003e\"},{\"header\":\"Material and Methods\",\"content\":\"\\u003cdiv id=\\\"Sec3\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003ePatient selection\\u003c/h2\\u003e \\u003cp\\u003eA retrospective analysis was conducted on 150 consecutive patients with EGJ carcinoma who underwent surgical resection at Tokyo Women\\u0026rsquo;s Medical University Hospital (Tokyo, Japan) between January 2004 and October 2020. EGJ carcinoma was defined according to Nishi\\u0026rsquo;s classification [\\u003cspan citationid=\\\"CR7\\\" class=\\\"CitationRef\\\"\\u003e7\\u003c/span\\u003e]. Tumors with their tumor epicenter located between 2 cm proximal and distal from the anatomical EGJ, irrespective of histology, were classified as EGJ carcinomas. Anatomical EGJ was identified from the resected specimen and was defined as the distal end of palisade vessels or deep esophageal glands and ducts. When the EGJ could not be detected microscopically due to tumor invasion, the level of macroscopic caliber change was used to define EGJ.\\u003c/p\\u003e \\u003cp\\u003eAll patients had pretreatment evaluation that included esophagogastroduodenoscopy (EGD) with biopsies, computed tomography scan (CT) from the chest to the pelvis, and/or positron emission tomography (PET). Staging was classified according to the 8th TNM staging system of the Union for International Cancer Control. The inclusion criteria were as follows: (1) pathologically diagnosed squamous cell carcinoma (including basaloid squamous cell carcinoma) or adenocarcinoma, except for adenosquamous carcinoma; (2) no residual tumor under microscope (R0); (3) without concomitant or prior malignancy within 5 years; (4) no history of preoperative endoscopic resection of the primary lesion; (5) not M1 disease at the time of initial diagnosis; (6) pathologically Stage IIA to IVA (T2-4 or N(+), except for M1); (7) followed up with periodic CT and EGD after surgery. This study was approved by the Ethics Review Board of Tokyo Women\\u0026rsquo;s Medical University (Approval number: 4582).\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec4\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003eSurgery and perioperative treatment\\u003c/h2\\u003e \\u003cp\\u003eThe choice of surgical procedure was determined by the length of esophageal involvement, the general condition of the patients, and the experience of the surgeons. For AC with esophageal involvement over 3 cm, transthoracic approach was commonly selected. For AC with esophageal involvement less than 3 cm, transabdominal lower esophagectomy with proximal or total gastrectomy was prevalently performed. For SCC, transthoracic surgery was performed in principle. As for abdominal lymphadenectomy, paracardial, along the left gastric artery, lesser curvature lymph nodes (LNs) along the branches of the left gastric artery, in the esophageal hiatus, and clinically positive LNs were routinely resected. Mediastinal lymphadenectomy included periesophageal and infracarinal when a transthoracic approach was used; the lower mediastinal nodes up to the level of the proximal margin were included with a transabdominal approach. The extent of further lymphadenectomy (including 106rec) depended on the preoperative findings. Digestive tract reconstruction involved the stomach or jejunum. The Clavien-Dindo (CD) classification system was used to assess postoperative complications [\\u003cspan citationid=\\\"CR8\\\" class=\\\"CitationRef\\\"\\u003e8\\u003c/span\\u003e]. Patients with grade\\u0026thinsp;\\u0026ge;\\u0026thinsp;2 complications were classified as having complications.\\u003c/p\\u003e \\u003cp\\u003eFor patients with an estimated high risk of postoperative relapse (i.e., T stage\\u0026thinsp;\\u0026gt;\\u0026thinsp;3 and/or positive N status) and with tolerable organ functions, platinum- or taxane-based neoadjuvant chemotherapy with or without concurrent 40Gy of radiotherapy, and/or adjuvant chemotherapy were performed (Supplementary Table\\u0026nbsp;1).\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec5\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003ePostoperative surveillance\\u003c/h2\\u003e \\u003cp\\u003eAfter surgery, the patients were followed up every three months for the first two years, semiannually for the next three years, and annually thereafter. During follow-up, blood tests and a CT scan from the chest to the pelvis were performed at every scheduled interval. EGD was conducted annually. When cancer recurrence was suspected on CT images or laboratory data, positron emission tomography-computed tomography (PET-CT) was additionally performed.\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec6\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003ePattern of recurrence\\u003c/h2\\u003e \\u003cp\\u003eRecurrences were diagnosed with histological, cytological, or definite radiological proof. Only the first episode of recurrence was used for analysis. For cases of concurrent multifocal recurrences, each categorized pattern was counted. The local area was defined to include tumor bed, anastomosis, remnant esophagus, and remnant stomach. The area of group 1 and 2 LNs of the Ae (zone of the EGJ) regional tumor on the 11th edition of Japanese Classification of Esophageal Cancer was defined as the regional area [\\u003cspan citationid=\\\"CR9\\\" class=\\\"CitationRef\\\"\\u003e9\\u003c/span\\u003e].\\u003c/p\\u003e \\u003cp\\u003ePatterns of recurrence were first categorized into local recurrence, regional lymph node metastasis, distant lymph node metastasis, distant organ metastasis, and peritoneal or pleural dissemination. Locoregional recurrences (LRR) and systemic metastases (SM) were then classified. Likewise, recurrence except for LN failure was classified as non-lymphogenous recurrence (NLR). The data was last updated in February 2023.\\u003c/p\\u003e \\u003c/div\\u003e \\u003cdiv id=\\\"Sec7\\\" class=\\\"Section2\\\"\\u003e \\u003ch2\\u003eStatistical analysis\\u003c/h2\\u003e \\u003cp\\u003eContinuous variables were compared using the Welch\\u0026rsquo;s t-test. Categorical variables were compared using the Chi-square test. Age, primary tumor length, and number of examined LNs were grouped by the median value as a cut-off. Survival times were defined from the date of surgery. The timing of recurrence was calculated from the day of surgery to the first event. The Kaplan-Meier method was used to analyze survival times, and Log-rank test was used to examine intergroup differences. Univariate Cox proportional hazards regression model was used to analyze prognostic factors, and Fine-Gray proportional hazards regression model was used in the multivariate analysis. Covariates with P\\u0026thinsp;\\u0026lt;\\u0026thinsp;0.1 in the univariate analysis were entered into the multivariate analysis and the backward stepwise method was used to optimize the model. Statistical analyses were conducted using R software version 4.1.2 (The R Foundation for Statistical Computing, Vienna, Austria). P\\u0026thinsp;\\u0026lt;\\u0026thinsp;0.05 was considered statistically significant.\\u003c/p\\u003e \\u003c/div\\u003e\"},{\"header\":\"Results\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003ePatient characteristics\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eA total of 102 eligible patients with EGJ cancer were analyzed: 48 with SCC and 54 with AC (Fig. 1). The median age of the whole group was 67 years (range, 42-85 years) and the median longitudinal length of the primary tumor in the resected specimen was 53 mm (range, 10-110 mm). A summary of the comparisons between the histology groups is provided in Table 1. An analysis of the patient characteristics revealed no significant intergroup differences in terms of age, tumor diameter and location, number of metastatic LNs, pathological T, N, and TNM stages, lymphatic and venous microinvasions, differentiation of tumor cells, and postoperative complication. Compared to patients with SCC, patients with AC were more frequently male (88.8% vs 64.6%; P = 0.007) and underwent transabdominal surgery more often (38.9% vs 6.3%; P \\u0026lt; 0.001). Accordingly, a larger number of LNs were examined in the SCC group (mean number = 21.7 vs 27.9; P = 0.019). A total of 68 patients (66.7%) were administered perioperative treatment. Adjuvant treatment was more frequently administered for AC (57.4% vs 35.4%; P = 0.043), although the frequency of neoadjuvant treatment showed no significant difference (16.7% vs 31.3%; P = 0.134). The aggregate frequency of perioperative treatment was comparable (68.5% vs 64.6%; P = 0.833).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eRecurrence pattern\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAfter a median follow-up time of 70.1 months (interquartile range [IQR],\\u0026nbsp;67.1-95.0 months) for SCC and 70.9 month (IQR, 43.9-98.7 months) for AC in the patients who remained alive, 21 patients (43.8%) with SCC and 33 patients (61.1%) with AC experienced recurrences. The 5-year overall survival (OS) and relapse-free survival (RFS) ratio for SCC vs. AC were 53.7 vs. 39.6% (P = 0.470; Fig. 2a) and 45.0 vs. 33.8% (P = 0.613; Fig. 2b), respectively. A total of 17 patients (35.4%, 7 above and 11 below the diaphragm) experienced LN failure and 7 (14.6%) showed NLR in patients with SCC. In the AC group, 14 patients (25.9%, 6 above and 8 below the diaphragm) showed LN failure and 20 (37.0%) showed NLR (Table 2). The AC group demonstrated a comparable LN failure-free survival (P = 0.291; Fig. 3a) and a significantly worse NLR-free survival (P = 0.035; Fig. 3b) compared with the SCC group.\\u003c/p\\u003e\\n\\u003cp\\u003eRegarding the areas of relapse, 9 (18.8 %) LRRs and 17 (35.4%) SMs occurred in the SCC group, and 9 (16.7%) LRRs and 27 (50.0%) SMs were observed in the AC group. Both LRR-free and SM-free survivals were comparable between histological subtypes (P = 0.696 and 0.339, respectively). Specific sites of recurrence are listed in Table 2. Liver was the most common distant metastasis site in both groups. Both pleural and peritoneal carcinomatosis were frequent in the AC group and the rate of dissemination was higher in the AC group, although it did not reach statistical significance (14.8% vs 2.1%; P = 0.063).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eRecurrence timing\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eFor patients who experienced recurrences, the median time to the first recurrence was 13.9 months (IQR, 5.9-20.9 months) after surgery in the AC group and 7.0 months (IQR, 4.5-8.7 months) in the SCC group, respectively. The statistical significance of a longer period from surgery to recurrence was observed in the AC group (P = 0.029). Overall, 76.2% of first recurrences for patients with SCC versus 45.5% for those with AC occurred within one year of follow-up. The surgery-to-NLR periods were significantly longer in the AC group (median, 12.2 vs 4.5 months; IQR, 3.8-18.4 vs 4.2-6.0 months; P = 0.007), whereas the surgery-to-LN failure periods were comparable between the two groups (median, 15.1 vs 7.2 months; IQR, 7.7-20.9 vs 4.7-13.3 months; P = 0.095). The timing and frequency of recurrences are listed in Table 3.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003ePrognostic factors for recurrence\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eUnivariate and multivariate analyses of prognostic factors for developing NLR were performed (Table 4). Multivariate analysis identified that histological subtype (P = 0.015, 95% CI = 1.24-7.28), pathological TNM stage (P = 0.002, 95% CI = 1.59-7.17), and differentiation (P = 0.029, 95% CI = 1.09-4.89) were independent predictive factors of NLR.\\u003c/p\\u003e\"},{\"header\":\"Discussion\",\"content\":\"\\u003cp\\u003eEsophageal and EGJ AC have shown the highest rates of increase in incidence of any cancer over the past four decades, especially in high-income countries [\\u003cspan citationid=\\\"CR2\\\" class=\\\"CitationRef\\\"\\u003e2\\u003c/span\\u003e]. In recent years, EGJ AC has also increased in Japan [\\u003cspan citationid=\\\"CR3\\\" class=\\\"CitationRef\\\"\\u003e3\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR4\\\" class=\\\"CitationRef\\\"\\u003e4\\u003c/span\\u003e]. On the other hand, esophageal SCC accounts for up to 90% of cases of esophageal cancer worldwide; however, it is decreasing in Western countries [\\u003cspan citationid=\\\"CR5\\\" class=\\\"CitationRef\\\"\\u003e5\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR10\\\" class=\\\"CitationRef\\\"\\u003e10\\u003c/span\\u003e]. These two distinct tumors tend to be considered to share similar characteristics and their differences have rarely been investigated. However, in addition to the previously observed greater male predominance of esophageal AC than esophageal SCC, other differences may also exist [\\u003cspan citationid=\\\"CR11\\\" class=\\\"CitationRef\\\"\\u003e11\\u003c/span\\u003e].\\u003c/p\\u003e \\u003cp\\u003eRegarding differences in the post-therapeutic outcomes, Siewert et al. reported a worse long-term survival among esophageal SCC patients compared to AC patients in patients undergoing surgery alone at the beginning of the twenty-first century [\\u003cspan citationid=\\\"CR12\\\" class=\\\"CitationRef\\\"\\u003e12\\u003c/span\\u003e]. Thereafter, the CROSS trial demonstrated similar LRR rates between the two histology groups of esophageal or EGJ cancer, in patients who received neoadjuvant CRT followed by surgery, whereas a higher risk of LRR for SCC was observed in patients who only underwent surgery [\\u003cspan citationid=\\\"CR13\\\" class=\\\"CitationRef\\\"\\u003e13\\u003c/span\\u003e]. As for systemic failure, conflicting outcomes regarding its likeliness in relation with histology, brought by varied protocols of trimodality therapy, have been reported [\\u003cspan citationid=\\\"CR14\\\" class=\\\"CitationRef\\\"\\u003e14\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR15\\\" class=\\\"CitationRef\\\"\\u003e15\\u003c/span\\u003e]. Concerning treatment modalities other than surgery-based treatment, Xi et al. retrospectively compared esophageal cancer cases by definitive CRT and reported significantly more favorable hematogenous failure-free survival in SCC patients and significantly higher rates of distant failure in AC patients [\\u003cspan citationid=\\\"CR16\\\" class=\\\"CitationRef\\\"\\u003e16\\u003c/span\\u003e]. However, the locational distributions of the two histological subtypes can vary, and previous studies present a bias in terms of tumor location between the two histological subtypes.\\u003c/p\\u003e \\u003cp\\u003eThis study is the first to compare postoperative recurrence patterns and timing between histological subtypes in an EGJ-limited-cancer cohort and identify differences. As a result, a significantly worse postoperative non-lymphogenous failure-free survival and significantly longer period from surgery to recurrence was observed in the AC group compared to the SCC group. In contrast, a relatively higher recurrence rate at LN was observed in the SCC group, even though the SCC group showed a larger number of harvested LNs and a smaller number of metastatic LNs. Studies involving lager cohorts that focused on individual histological subtypes have shown that the primary cause of postoperative failure in esophageal SCC was often LN metastasis [\\u003cspan citationid=\\\"CR17\\\" class=\\\"CitationRef\\\"\\u003e17\\u003c/span\\u003e]. Conversely, LN metastasis was a less common factor contributing to postoperative failure in EGJ AC [\\u003cspan citationid=\\\"CR18\\\" class=\\\"CitationRef\\\"\\u003e18\\u003c/span\\u003e]. The findings of the present study agree with those of previous studies, suggesting that assessing tumor-spreading appearance based on a viewpoint lymphogenous or non-lymphogenous, rather than focusing solely on locoregional or systemic aspects, may provide more informative insights.\\u003c/p\\u003e \\u003cp\\u003eConcerning recurrence timing, median time-to-recurrence after surgery in esophageal and EGJ AC has been reported within a range of between 11 and 26 months [\\u003cspan additionalcitationids=\\\"CR20\\\" citationid=\\\"CR19\\\" class=\\\"CitationRef\\\"\\u003e19\\u003c/span\\u003e\\u0026ndash;\\u003cspan citationid=\\\"CR21\\\" class=\\\"CitationRef\\\"\\u003e21\\u003c/span\\u003e]. In esophageal SCC, Kurogochi et al. reported that over 70% of postoperative recurrence occurred within one year [\\u003cspan citationid=\\\"CR22\\\" class=\\\"CitationRef\\\"\\u003e22\\u003c/span\\u003e]. To the best of our knowledge, there have been no direct comparisons of the timing of postoperative recurrence between histological subtypes in esophageal or EGJ cancer. Yun et al. directly compared the timing of recurrence after surgery for non-small cell lung cancer and found varied peaks of recurrence hazard depending on tumor histology; 9 months in SCC and 15 months in AC [\\u003cspan citationid=\\\"CR23\\\" class=\\\"CitationRef\\\"\\u003e23\\u003c/span\\u003e]. These findings closely resemble our results, suggesting that longer periods until recurrence in AC than in SCC may be a common tumoral characteristic across primary organs, considering findings in the field of lung cancer.\\u003c/p\\u003e \\u003cp\\u003eTreatment strategies for esophageal and EGJ AC have mainly been developed in Western countries. In the CROSS trial, conducted in a cohort among which 75% of patients had esophageal or EGJ AC, the effect of neoadjuvant chemoradiotherapy tended to be lower for AC than for SCC. Furthermore, the ten-year outcomes did not show significant survival superiority in the AC group [\\u003cspan citationid=\\\"CR24\\\" class=\\\"CitationRef\\\"\\u003e24\\u003c/span\\u003e, \\u003cspan citationid=\\\"CR25\\\" class=\\\"CitationRef\\\"\\u003e25\\u003c/span\\u003e]. A high ratio (28.6%) of hematogenous recurrence after the neoadjuvant chemoradiotherapy was also noted.\\u003csup\\u003e13\\u003c/sup\\u003e The FLOT4-AIO trial demonstrated a significantly enhanced outcome with perioperative FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) therapy for EGJ and gastric AC, compared with perioperative ECF/ECX (MAGIC regimen) therapy [\\u003cspan citationid=\\\"CR26\\\" class=\\\"CitationRef\\\"\\u003e26\\u003c/span\\u003e]. For esophageal or EGJ cancer after neoadjuvant CRT, significantly longer disease-free survival for both AC and SCC were associated with adjuvant nivolumab therapy in the Checkmate 577 trial [\\u003cspan citationid=\\\"CR27\\\" class=\\\"CitationRef\\\"\\u003e27\\u003c/span\\u003e]. In the Neo-AEGIS trial, trimodality therapy was directly compared with perioperative chemotherapy for AC of the esophagus and EGJ [\\u003cspan citationid=\\\"CR28\\\" class=\\\"CitationRef\\\"\\u003e28\\u003c/span\\u003e]. This study ended in equipoise, with significantly fewer liver and lung metastases in the perioperative chemotherapy group.\\u003c/p\\u003e \\u003cp\\u003eThe current study indicates that EGJ AC may exhibit a stronger tendency for non-lymphogenous progression compared to EGJ SCC. This may be a favorable factor for treatment emphasizing systemic control since non-lymphogenous progression is more challenging to manage through surgical resection or by radiation therapy than progression through the lymphatic system. Comprehensively, both the findings reported in the literature and the results of the present study suggest that perioperative systemic treatment would be promising for EGJ AC.\\u003c/p\\u003e \\u003cp\\u003eThis study has some limitations, including its retrospective, single-center design. Possibility of selection bias cannot be excluded. Second, variations of treatments could have influenced the results. Surgical approach and the extent of LN dissection, where a consensus has not made, varied between the subgroups while R0 was secured in all cases, and both the incidence of postoperative complication and the distribution of LN metastasis site were comparable. Differences in perioperative treatments also might have affected the result. Third is the small number of the cases. Nevertheless, given the rarity of EGJ SCC, we believe this study is valuable in terms of the study of aspects that have rarely been investigated before. Furthermore, this study is the first to note the different pattern and varied timing of postoperative recurrence in EGJ cancers. Future research with larger and characteristically well-matched cohorts to verify these findings will be desirable and beneficial.\\u003c/p\\u003e\"},{\"header\":\"Conclusions\",\"content\":\"\\u003cp\\u003eEGJ AC showed a stronger tendency for non-lymphogenous progression and a propensity for longer surgery-to-recurrence period compared to EGJ SCC. Thus, emphasizing perioperative systemic control would be suitable for resectable locally advanced EGJ AC. In this context, careful attention should be paid to the different patterns and timing of recurrence for the different histological subtypes of EGJ cancer in the postoperative follow-up period.\\u003c/p\\u003e\"},{\"header\":\"Declarations\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eAcknowledgments\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eWe would like to thank Editage (www.editage.jp) for English language editing.\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eEthics Statements\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThis study was conducted with approval of the Ethics Review Board of Tokyo Women\\u0026rsquo;s Medical University (Approval number: 4582) and conforms to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). Requirement for written informed consent was waived due to the retrospective design.\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eCompeting Interests\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe Authors declare that they have no conflicts of interest in relation to this study.\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eFunding Information\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eNo funding was received for conducting this study.\\u0026nbsp;\\u003c/p\\u003e\\u003ch2\\u003eAuthor Contribution\\u003c/h2\\u003e\\u003cp\\u003eS.M. and M.O. substantially contributed to the study design. S.M. and S.I. significantly contributed to data acquisition, analysis, and interpretation. S.M. and K.H. substantially contributed to the manuscript drafting. All authors reviewed the manuscript.\\u003c/p\\u003e\"},{\"header\":\"References\",\"content\":\"\\u003col\\u003e\\n\\u003cli\\u003eSung H, Ferlay J, Siegel RL, et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-49.https://doi.org/10.3322/caac.21660\\u003c/li\\u003e\\n\\u003cli\\u003eColeman HG, Xie SH, Lagergren J (2018) The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 154(2):390\\u0026ndash;405.https://doi.org/10.1053/j.gastro.2017.07.046\\u003c/li\\u003e\\n\\u003cli\\u003eKusano C, Gotoda T, Khor CJ, et al (2008) Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 23(11):1662-5.https://doi.org/10.1111/j.1440-1746.2008.05572.x\\u003c/li\\u003e\\n\\u003cli\\u003eYamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M (2017) Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 20:69\\u0026ndash;83.https://doi.org/10.1007/s10120-016-0663-8\\u003c/li\\u003e\\n\\u003cli\\u003eObermannov\\u0026aacute; R, Alsina M, Cervantes A, et al (2022) Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 33(10):992\\u0026ndash;1004.https://doi.org/10.1016/j.annonc.2022.07.003\\u003c/li\\u003e\\n\\u003cli\\u003eKato K, Ito Y, Daiko H, et al (2022) A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 40(4_suppl):238.https://doi.org/10.1200/jco.2022.40.4_suppl.238\\u003c/li\\u003e\\n\\u003cli\\u003eJapan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus. 14(1):37-65.https://doi.org/10.1007/s10388-016-0556-2\\u003c/li\\u003e\\n\\u003cli\\u003eDindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240(2):205-13.https://doi.org/10.1097/01.sla.0000133083.54934.ae\\u003c/li\\u003e\\n\\u003cli\\u003eJapan Esophageal Society (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 14(1):1-36.https://doi.org/10.1007/s10388-016-0551-7\\u003c/li\\u003e\\n\\u003cli\\u003eArnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64(3):381\\u0026ndash;7.https://doi.org/10.1136/gutjnl-2014-308124\\u003c/li\\u003e\\n\\u003cli\\u003eTurner KO, Genta RM, Sonnenberg A (2015) Oesophageal signet ring cell carcinoma as complication of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 42(10):1221-31.https://doi.org/10.1111/apt.13395\\u003c/li\\u003e\\n\\u003cli\\u003eSiewert JR, Engl F, Stein HJ, et al (2001) Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World. Ann Surg. 234:360\\u0026ndash;7.https://doi.org/10.1097/00000658-200109000-00010\\u003c/li\\u003e\\n\\u003cli\\u003eOppedijk V, Van Der Gaast A, Van Lanschot JJB, et al (2014) Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 32(5):385\\u0026ndash;91.https://doi.org/10.1200/JCO.2013.51.2186\\u003c/li\\u003e\\n\\u003cli\\u003eRobb WB, Messager M, Dahan L, et al (2016) Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 103(1):117\\u0026ndash;25.https://doi.org/10.1002/bjs.9959\\u003c/li\\u003e\\n\\u003cli\\u003eKoshy M, Greenwald BD, Hausner P, et al (2011) Outcomes after trimodality therapy for esophageal cancer: The impact of histology on failure patterns. Am J Clin Oncol. 34(3):259\\u0026ndash;64.https://doi.org/10.1097/COC.0b013e3181e841ce\\u003c/li\\u003e\\n\\u003cli\\u003eXi M, Xu C, Liao Z, et al (2017) The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 124(2):318\\u0026ndash;24.https://doi.org/10.1016/j.radonc.2017.06.019\\u003c/li\\u003e\\n\\u003cli\\u003eSugimura K, Miyata H, Kanemura T, et al (2023) Patterns of Recurrence and Long-Term Survival of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Locally Advanced Esophageal Cancer Treated with Neoadjuvant Chemotherapy: a Propensity Score\\u0026ndash;Matched Analysis. J Gastrointest Surg. 27(6):1055-65.https://doi.org/10.1007/s11605-023-05615-x\\u003c/li\\u003e\\n\\u003cli\\u003eNakauchi M, Vos EL, Carr RA, et al (2023) Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021. Ann Surg. 277(4):629\\u0026ndash;36.https://doi.org/10.1097/SLA.0000000000005320\\u003c/li\\u003e\\n\\u003cli\\u003ede Manzoni G, Pedrazzani C, Pasini F, et al (2003) Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol. 29(6):506\\u0026ndash;10.https://doi.org/10.1016/S0748-7983(03)00098-2\\u003c/li\\u003e\\n\\u003cli\\u003eHosokawa Y, Kinoshita T, Konishi M, et al (2014) Recurrence patterns of esophagogastric junction adenocarcinoma according to Siewert\\u0026rsquo;s classification after radical resection. Anticancer Res. 34(8):4391-7.\\u003c/li\\u003e\\n\\u003cli\\u003eAbate E, DeMeester SR, Zehetner J, et al (2010) Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and Testing. J Am Coll Surg. 210(4):428-35.https://doi.org/10.1016/j.jamcollsurg.2010.01.006\\u003c/li\\u003e\\n\\u003cli\\u003eKurogochi T, Honda M, Takahashi K, et al (2022) Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer. Surg Today. 52(4):660\\u0026ndash;7.https://doi.org/10.1007/s00595-021-02397-0\\u003c/li\\u003e\\n\\u003cli\\u003eYun JK, Lee GD, Choi S, et al (2022) Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection. Transl Lung Cancer Res. 11(7):1327\\u0026ndash;36.https://doi.org/10.21037/tlcr-21-1028\\u003c/li\\u003e\\n\\u003cli\\u003eVan Hagen P, Hulshof MCCM, Van Lanschot JJB, et al (2012) Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med. 366:2074\\u0026ndash;84.https://doi.org/10.1056/NEJMoa1112088\\u003c/li\\u003e\\n\\u003cli\\u003eEyck BM, Van Lanschot JJB, Hulshof MCCM, et al (2021) Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 39:1995\\u0026ndash;2004.https://doi.org/ 10.1200/JCO.20.03614\\u003c/li\\u003e\\n\\u003cli\\u003eAl-Batran SE, Homann N, Pauligk C, et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 393(10184):1948\\u0026ndash;57.https://doi.org/10.1016/S0140-6736(18)32557-1\\u003c/li\\u003e\\n\\u003cli\\u003eKelly RJ, Ajani JA, Kuzdzal J, et al (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 384(13):1191-203.https://doi.org/10.1056/nejmoa2032125\\u003c/li\\u003e\\n\\u003cli\\u003eReynolds JV, Preston SR, O\\u0026rsquo;Neill B, et al (2023) Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 8(11):1015\\u0026ndash;27. https://doi.org/10.1016/S2468-1253(23)00243-1\\u003c/li\\u003e\\n\\u003c/ol\\u003e\"},{\"header\":\"Tables\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eTable 1\\u003c/strong\\u003e\\u0026nbsp; Background characteristics and pathological findings of the patients\\u003c/p\\u003e\\n\\u003cdiv align=\\\"\\\"\\u003e\\n \\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"699\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\" rowspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003eCharacteristic\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003eAll patients (n = 102)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003eSCC (n = 48)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003eAC (n = 54)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" rowspan=\\\"2\\\"\\u003e\\n \\u003cp\\u003ep Value\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"40.57142857142857%\\\"\\u003e\\n \\u003cp\\u003en (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"29.714285714285715%\\\"\\u003e\\n \\u003cp\\u003en (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"29.714285714285715%\\\"\\u003e\\n \\u003cp\\u003en (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eAge, years\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.094\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eMedian\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e67\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e69.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e67\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eRange\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e42-85\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e48-85\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e42-84\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eGender\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.007\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eMale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e79 (77.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e31 (63.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e48 (88.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eFemale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e23 (22.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (35.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e6 (11.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eTumor diameter, mm\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.549\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Median\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e52.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp; Range\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e10-110\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e10-105\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e16-110\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eTumor location\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.269\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eAcross the EGJ\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e94 (92.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e43 (89.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e51 (94.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eEsophagus only\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e7 (6.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e5 (10.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e2 (3.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eStomach only\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e1 (1.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e0 (0.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e1 (1.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eSurgical procedure\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026lt;0.001\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eTransthoracic\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e78 (76.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e45 (93.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e33 (61.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eTransabdominal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e24 (23.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e3 (6.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e21 (38.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNumber of examined LNs (mean \\u0026plusmn; SD)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e24.6 \\u0026plusmn; 13.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e27.9 \\u0026plusmn; 14.1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e21.7 \\u0026plusmn; 11.5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.019\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNumber of metastatic LNs (mean \\u0026plusmn; SD)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e3.10 \\u0026plusmn; 3.59\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e2.60 \\u0026plusmn; 2.83\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e3.54 \\u0026plusmn; 4.12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.182\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePostoperative complication\\u003csup\\u003ea\\u003c/sup\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e1.00\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eYes\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e21 (20.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e10 (20.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e11 (20.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNo\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e81 (79.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e38 (79.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e43 (79.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePerioperative treatment (+/-)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.833\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eYes\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e68 (66.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e31 (64.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e37 (68.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNo\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e34 (33.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (35.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (31.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNeoadjuvant treatment (+/-)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.134\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eYes\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e24 (23.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e15 (31.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e9 (16.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNo\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e78 (76.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e33 (68.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e45 (83.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eAdjuvant treatment (+/-)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.043\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eYes\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e48 (47.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (35.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e31 (57.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNo\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e54 (52.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e31 (64.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e23 (42.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePathological T stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.378\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e8 (78.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e3 (6.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e5 (9.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e11 (10.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e4 (3.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e7 (13.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e81 (79.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e39 (81.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e42 (77.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e2 (2.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e2 (4.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e0 (0.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePathological N stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.164\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e30 (29.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e14 (29.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e16 (29.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e32 (31.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e15 (14.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (35.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e22 (21.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e14 (29.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e8 (14.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e18 (17.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e5 (4.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e13 (24.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePathological TNM stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.150\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eIIA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e7 (6.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e4 (8.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e3 (5.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eIIB\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e29 (28.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e12 (25.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e17 (31.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eIIIA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e6 (5.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e1 (2.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e5 (9.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eIIIB\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e40 (39.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e24 (50.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e16 (29.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eIVA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e20 (19.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e7 (14.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e13 (24.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eLymphatic microinvasion\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e1.00\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNone or slight\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e47 (46.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e22 (45.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e25 (46.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eModerate or severe\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e55 (53.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e26 (54.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e29 (53.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eVenous microinvasion\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.948\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eNone or slight\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e73 (71.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e35 (72.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e38 (70.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eModerate or severe\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e29 (28.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e13 (27.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e16 (29.6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eDifferentiation of tumor cells\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\" valign=\\\"top\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e0.530\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003eWell or moderate\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e68 (66.7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e34 (70.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e34 (63.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"36.42857142857143%\\\"\\u003e\\n \\u003cp\\u003ePoor\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"20.285714285714285%\\\"\\u003e\\n \\u003cp\\u003e34 (33.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e14 (29.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"14.857142857142858%\\\"\\u003e\\n \\u003cp\\u003e20 (37.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.571428571428571%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n \\u003c/table\\u003e\\n\\u003c/div\\u003e\\n\\u003cp\\u003e\\u003csup\\u003ea\\u003c/sup\\u003e Grade \\u0026sup3; 2 according to the Clavien-Dindo (CD) classification system\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003csup\\u003eb\\u003c/sup\\u003e The 8th TNM staging system of the Union for International Cancer Control (UICC)\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003eSCC\\u003c/em\\u003e squamous cell carcinoma, \\u003cem\\u003eAC\\u003c/em\\u003e adenocarcinoma, \\u003cem\\u003eEGJ\\u003c/em\\u003e esophagogastric junction, \\u003cem\\u003eLN\\u003c/em\\u003e lymph node,\\u0026nbsp;\\u003cem\\u003eCD\\u003c/em\\u003e Clavien-Dindo\\u003cbr\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 2\\u003c/strong\\u003e\\u0026nbsp; Recurrence patterns\\u003c/p\\u003e\\n\\u003cdiv align=\\\"\\\"\\u003e\\n \\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"492\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003e \\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003eSCC (n = 48)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003eAC (n = 54)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eNo. of patients with any relapse: n (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e21 (43.8)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e33 (61.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eLymphogenous: n (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e17 (35.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e14 (25.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eRegional LN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003e(above / below the diaphragm)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e(2/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e(1/2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eDistant LN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e14\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003e(above / below the diaphragm)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e(7/7)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e(6/6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eNon-lymphogenous: n (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e7 (14.6)\\u003csup\\u003ea\\u003c/sup\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e20 (37.0)\\u003csup\\u003ea\\u003c/sup\\u003e\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eLocal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eAnastomosis\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eTumor bed\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eRemnant esophagus\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eSystemic\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eLiver\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eLung\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eBone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eAdrenal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003eHeart\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003ePleura\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"49.59349593495935%\\\"\\u003e\\n \\u003cp\\u003ePeritoneum\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"25.203252032520325%\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n \\u003c/table\\u003e\\n\\u003c/div\\u003e\\n\\u003cp\\u003e\\u003csup\\u003ea\\u003c/sup\\u003e p \\u0026lt; 0.05\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003eSCC\\u003c/em\\u003e squamous cell carcinoma, \\u003cem\\u003eAC\\u003c/em\\u003e adenocarcinoma, \\u003cem\\u003eLN\\u003c/em\\u003e lymph node\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 3\\u003c/strong\\u003e\\u0026nbsp; Timing and frequency of recurrences\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cimg src=\\\"data:image/png;base64,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\\\" style=\\\"width: 1225px; height: 687.632px;\\\" width=\\\"1225\\\" height=\\\"687.632\\\"\\u003e\\u003cbr\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003csup\\u003ea\\u003c/sup\\u003e p \\u0026lt; 0.05\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003eSCC\\u003c/em\\u003e squamous cell carcinoma, \\u003cem\\u003eAC\\u003c/em\\u003e adenocarcinoma\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 4\\u003c/strong\\u003e \\u0026nbsp;Univariate and multivariate analyses for non-lymphogenous recurrence\\u003c/p\\u003e\\n\\u003ctable border=\\\"0\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" align=\\\"\\\" width=\\\"747\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.309236947791163%\\\" rowspan=\\\"2\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eVariable\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.165997322623829%\\\" rowspan=\\\"2\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003en\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.670682730923694%\\\" rowspan=\\\"2\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003eIncidence\\u003cbr\\u003e\\u0026nbsp;n (%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"21.552878179384205%\\\" colspan=\\\"2\\\" style=\\\"width: 38.642%;\\\"\\u003e\\n \\u003cp\\u003eUnivariate\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"23.29317269076305%\\\" colspan=\\\"2\\\" style=\\\"width: 11.2872%;\\\"\\u003e\\n \\u003cp\\u003eMultivariate\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"32.378223495702%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003eHazard ratio (95% CI)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"13.46704871060172%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003ep Value\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"33.5243553008596%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\n \\u003cp\\u003eHazard ratio (95% CI)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"16.332378223495702%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\n \\u003cp\\u003ep Value\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eAge\\u003cbr\\u003e\\u0026nbsp;\\u0026lt;68 /\\u0026nbsp;\\u0026sup3;68\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e52 / 50\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e19 (36.5) / 12 (24.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e0.63 (0.29-1.37)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.244\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eGender\\u003cbr\\u003e\\u0026nbsp;male / female\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e79 / 23\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e23 (29.1) / 4 (17.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e0.62 (0.22-1.81)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.385\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eHistological subtype\\u003cbr\\u003e\\u0026nbsp;SCC / AC\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e48 / 54\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e7 (14.6) / 20 (37.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e2.45 (1.04-5.81)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.041\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\n \\u003cp\\u003e3.00 (1.24-7.28)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.015\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eTumor length\\u003cbr\\u003e\\u0026nbsp;\\u0026pound;5.0 / \\u0026gt;5.0 cm\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e47 / 55\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e11 (23.4) / 16 (29.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e1.43 (0.67-3.09)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.358\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eSurgical approach\\u003cbr\\u003e\\u0026nbsp;transhiatal / transthoracic\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e24 / 78\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e9 (37.5) / 18 (23.1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e0.63 (0.28-1.40)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.257\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eNumber of examined LNs\\u003cbr\\u003e\\u0026nbsp;\\u0026lt;24 /\\u0026nbsp;\\u0026sup3;24\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e52 / 50\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e14 (26.9) / 13 (26.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e0.94 (0.44-2.01)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.883\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003ePostoperative complication\\u003csup\\u003ea\\u003c/sup\\u003e\\u003cbr\\u003e\\u0026nbsp;- / +\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e81 / 21\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e21 (25.9) / 6 (28.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e1.15 (0.46-2.85)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.765\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003ePathological T stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003cbr\\u003e\\u0026nbsp;T1-2 / T3-4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e19 / 83\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e3 (15.8) / 24 (28.9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e2.41 (0.72-8.01)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.152\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003ePathological N stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003cbr\\u003e\\u0026nbsp;N0-1 / N2-3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e62 / 40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e13 (21.0) / 14 (35.0)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e2.73 (1.26-5.89)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.011\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003ePathological TNM stage\\u003csup\\u003eb\\u003c/sup\\u003e\\u003cbr\\u003e\\u0026nbsp;IIA-IIIA / IIIB-IVA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e42 / 60\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e7 (16.7) / 20 (33.3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e3.12 (1.31-7.44)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.010\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\n \\u003cp\\u003e3.37 (1.59-7.17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.002\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eLympatic microinvasion\\u003cbr\\u003e\\u0026nbsp;none or slight / mod or more\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e47 / 55\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e7 (14.9) / 20 (36.4)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e3.48 (1.46-8.26)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.005\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eVenous microinvasion\\u003cbr\\u003e\\u0026nbsp;none or slight / mod or more\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e73 / 29\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e17 (23.3) / 10 (34.5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e1.85 (0.84-4.07)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e0.125\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd width=\\\"27.345844504021446%\\\" style=\\\"width: 24.1678%;\\\"\\u003e\\n \\u003cp\\u003eDifferentiation\\u003cbr\\u003e\\u0026nbsp;well or moderate / other\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"8.176943699731904%\\\" style=\\\"width: 6.9051%;\\\"\\u003e\\n \\u003cp\\u003e68 / 34\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"17.694369973190348%\\\" style=\\\"width: 15.6693%;\\\"\\u003e\\n \\u003cp\\u003e13 (19.1) / 14 (41.2)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.14745308310992%\\\" style=\\\"width: 26.9564%;\\\"\\u003e\\n \\u003cp\\u003e2.52 (1.19-5.38)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"6.3002680965147455%\\\" style=\\\"width: 11.6856%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.016\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"15.683646112600536%\\\" style=\\\"width: 6.2411%;\\\"\\u003e\\n \\u003cp\\u003e2.31 (1.09-4.89)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd width=\\\"7.640750670241287%\\\" style=\\\"width: 5.046%;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0.029\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u003csup\\u003ea\\u003c/sup\\u003e Grade\\u0026nbsp;\\u0026sup3;\\u0026nbsp;2 according to the Clavien-Dindo (CD) classification system\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003csup\\u003eb\\u003c/sup\\u003e The 8th TNM staging system of the Union for International Cancer Control (UICC)\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003eSCC\\u003c/em\\u003e squamous cell carcinoma, \\u003cem\\u003eAC\\u003c/em\\u003e adenocarcinoma, \\u003cem\\u003eCD\\u003c/em\\u003e Clavien-Dindo\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\"}],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":true,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":true,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":false,\"isAuthorSuppliedPdf\":false,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":false,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true},\"keywords\":\"esophagogastric junction, histological subtype, recurrence pattern, recurrence timing\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-4063105/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-4063105/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"\\u003ch2\\u003ePurpose\\u003c/h2\\u003e \\u003cp\\u003eThe differences of tumoral behavior between histological subtypes of esophagogastric junction (EGJ) cancer have yet to be well investigated. The purpose of this study is to gain insights that can contribute to the tailored treatments and follow-up strategies by analyzing correlation between histological subtypes and oncological outcomes.\\u003c/p\\u003e\\u003ch2\\u003eMethods\\u003c/h2\\u003e \\u003cp\\u003eRetrospective analysis was used to determine the characteristics of the histological subtype of EGJ cancer by comparing the appearance of postoperative recurrences. A total of 102 consecutive cases of pathological Stage IIA to IVA EGJ cancer, who underwent R0 surgery in our department from 2004 to 2020, were enrolled. The recurrence pattern, timing, survival, and potential prognostic factors were compared.\\u003c/p\\u003e\\u003ch2\\u003eResults\\u003c/h2\\u003e \\u003cp\\u003eAfter a median follow-up time of 70.1 months, the AC group demonstrated a comparable lymph node metastasis-free survival (P\\u0026thinsp;=\\u0026thinsp;0.291) and a significantly worse non-lymphogenous failure-free survival (P\\u0026thinsp;=\\u0026thinsp;0.035) than the SCC group. A significantly longer period from surgery to recurrence in the AC group was also observed (P\\u0026thinsp;=\\u0026thinsp;0.029). Multivariate analysis indicated that histological subtype (P\\u0026thinsp;=\\u0026thinsp;0.015, 95% CI\\u0026thinsp;=\\u0026thinsp;1.24\\u0026ndash;7.28) was significantly correlated with the incidence of non-lymphogenous recurrence.\\u003c/p\\u003e\\u003ch2\\u003eConclusions\\u003c/h2\\u003e \\u003cp\\u003eThe pattern and timing of postoperative recurrence for EGJ cancer were found to be significantly different between the histological subtypes. EGJ AC may have a stronger tendency of non-lymphogenous progression and a propensity for longer surgery-to-recurrence periods compared to EGJ SCC.\\u003c/p\\u003e\",\"manuscriptTitle\":\"The impact of histological subtype on postoperative recurrence pattern and timing in locally advanced esophagogastric junction cancer\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2024-03-13 17:20:36\",\"doi\":\"10.21203/rs.3.rs-4063105/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"researchsquare\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":true,\"externalIdentity\":\"\",\"sideBox\":\"\",\"snPcode\":\"\",\"submissionUrl\":\"/submission\",\"title\":\"Research Square\",\"twitterHandle\":\"researchsquare\",\"acdcEnabled\":true,\"dfaEnabled\":false,\"editorialSystem\":\"\",\"reportingPortfolio\":\"\",\"inReviewEnabled\":false,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"7b27e354-9c28-4da4-b6f5-fd4e0be06408\",\"owner\":[],\"postedDate\":\"March 13th, 2024\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"posted\",\"subjectAreas\":[],\"tags\":[],\"updatedAt\":\"2024-04-02T10:07:21+00:00\",\"versionOfRecord\":[],\"versionCreatedAt\":\"2024-03-13 17:20:36\",\"video\":\"\",\"vorDoi\":\"\",\"vorDoiUrl\":\"\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-4063105\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-4063105\",\"identity\":\"rs-4063105\",\"version\":[\"v1\"]},\"buildId\":\"qtupq5eGEP_6zYnWcrvyt\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}